

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 August 2006 (31.08.2006)

PCT

(10) International Publication Number
WO 2006/091871 A1

(51) International Patent Classification:

C07K 16/00 (2006.01) **C12N 5/00** (2006.01)
C07K 1/00 (2006.01) **A01K 67/033** (2006.01)
C07H 21/02 (2006.01) **A01N 37/18** (2006.01)
C12N 15/00 (2006.01) **A01N 43/04** (2006.01)

California 92122 (US). **KELLER, Gilbert, A.** [US/US];
2523 Carmelita Avenue, Belmont, California 94002 (US).
DYLAN, Tyler, M. [US/US]; 3363 Riviera Drive, San
Diego, California 92109 (US).

(21) International Application Number:

PCT/US2006/006700

(74) Agent: **HAILE, Lisa, A.**; DLA PIPER RUDNICK GRAY
CARY US LLP, 4365 Executive Drive, Suite 1100, San
Diego, California 92121 (US).

(22) International Filing Date:

23 February 2006 (23.02.2006)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

11/065,716 23 February 2005 (23.02.2005) US
11/238,171 27 September 2005 (27.09.2005) US

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US
(patent), UZ, VC, VN, YU, ZA, ZM, ZW.

(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:

US 11/065,716 (CIP)
Filed on 27 September 2005 (27.09.2005)

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*):
HALOZYME THERAPEUTICS, INC. [US/US];
11588 Sorrento Valley Road, Suite 17, San Diego, Cali-
fornia 92123 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BOOKBINDER,
Louis, H.** [US/US]; 14823 Gable Ridge Road, San Diego,
California 92128 (US). **KUNDU, Anirban** [IN/US]; 3535
Monroe Avenue, Apt. 24, San Diego, California 92116
(US). **FROST, Gregory, I.** [US/US]; 13662 Mercado
Drive, Del Mar, California 92014 (US). **HALLER,
Michael, F.** [US/US]; 3442 Villanova Avenue, San Diego,

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: SOLUBLE GLYCOSAMINOGLYCANASES AND METHODS OF PREPARING AND USING SOLUBLE GLY-
COSAMINOGLYCANASES

(57) Abstract: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.



WO 2006/091871 A1